{"entity":{"id":"paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020","kind":"paper","name":"Overall survival in anaplastic thyroid carcinoma 2000 to 2019: impact of targeted therapy and neoadjuvant BRAF-MEK inhibition","aka":[],"tldr":"At MD Anderson, survival in anaplastic thyroid cancer improved dramatically over two decades as BRAF testing, targeted therapy and neoadjuvant BRAF-MEK inhibition followed by surgery were introduced, with one-year survival rising from 35 to 59 percent.","summary":"Retrospective cohort study of 479 patients with anaplastic thyroid carcinoma treated at a single centre between 2000 and 2019, divided into three eras, examining the association of targeted therapy, immunotherapy and neoadjuvant BRAF-MEK inhibitor therapy with survival.\n\nOne-year overall survival rose from 35 percent (2000 to 2013) to 47 percent (2014 to 2016) and 59 percent (2017 to 2019); BRAF-mutant patients treated with neoadjuvant BRAF-directed therapy and surgery had 94 percent one-year survival.","asOf":"2026-09-17","links":[{"label":"JAMA Oncol 2020","url":"https://doi.org/10.1001/jamaoncol.2020.3362"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32761153/"}],"tags":[],"related":[],"cancers":["anaplastic-thyroid-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-oncology"],"dependsOn":[],"notes":[],"journal":"JAMA Oncology","year":2020,"doi":"10.1001/jamaoncol.2020.3362","pmid":"32761153","authors":"Maniakas A, Dadu R, Busaidy NL, et al.","paperType":"observational","findings":["One-year overall survival 35 percent, 47 percent and 59 percent across three eras.","Neoadjuvant BRAF-directed therapy with surgery: one-year survival 94 percent."],"whatItMeans":"Neoadjuvant dabrafenib-trametinib to convert unresectable BRAF-mutant anaplastic thyroid cancer into operable disease is now a guideline-endorsed strategy.","caveats":["Single-centre retrospective data with era and selection effects."],"changedPractice":true,"participants":479},"route":"/key-papers/paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020/","neighbours":{"cancer":[{"id":"anaplastic-thyroid-cancer","kind":"cancer","name":"Anaplastic thyroid cancer","route":"/cancers/anaplastic-thyroid-cancer/"}],"journal":[{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/"}]}}